Use of Celecoxib in Patients With Intraductal Papillary Mucinous Neoplasms (IPMNs)

• Status: Terminated
• Trial end date: 2012-04-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of the study is to find out whether the drug celecoxib has beneficial effects on people with pre-cancerous lesions of the pancreas.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Indiana University School of Medicine
• Treatments: Celecoxib; Cyclooxygenase 2 Inhibitors

Criteria

Inclusion Criteria:

• Clinical diagnosis of IPMN

• ECOG Performance status of 0, 1, or 2

• Adequate liver function, bilirubin < 1.5 times ULN, ALT or AST < 2.5 times ULN

• Adequate renal function: creatinine < 1.8

• Must be at least 18

Exclusion Criteria:

• Use of COX-2 selective inhibitors within the last month

• More than occasional use of NSAIDS in last month (occasional use defined as up to twice weekly dosing)

• CA19-9 levels 1.5 times the ULN

• Active pancreatitis

• Taking sulphonylureas, fluconazole or lithium concomitantly